Source: European Journal of Pharmaceutics and Biopharmaceutics. Unidades: FCF, IQ
Subjects: ARTERIOSCLEROSE, ESTRESSE OXIDATIVO, ÁCIDOS GRAXOS OMEGA 3, NANOTECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LEÃO, Matheus de Castro et al. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. European Journal of Pharmaceutics and Biopharmaceutics, v. 159, p. 99–107, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ejpb.2020.12.016. Acesso em: 16 maio 2024.APA
Leão, M. de C., Pohlmann, A. R., Alves, A. de C. S., Farsky, S. H. P., Uchiyama, M. K., Araki, K., et al. (2021). Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression. European Journal of Pharmaceutics and Biopharmaceutics, 159, 99–107. doi:10.1016/j.ejpb.2020.12.016NLM
Leão M de C, Pohlmann AR, Alves A de CS, Farsky SHP, Uchiyama MK, Araki K, Sandri S, Guterres SS, Castro IA de. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 159 99–107.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.ejpb.2020.12.016Vancouver
Leão M de C, Pohlmann AR, Alves A de CS, Farsky SHP, Uchiyama MK, Araki K, Sandri S, Guterres SS, Castro IA de. Docosahexaenoic acid nanoencapsulated with anti-PECAM-1 as co-therapy for atherosclerosis regression [Internet]. European Journal of Pharmaceutics and Biopharmaceutics. 2021 ; 159 99–107.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.ejpb.2020.12.016